Clinical and Molecular Predictors of Response and Survival in Patients with Urothelial Carcinoma Treated with Enfortumab Vedotin: A Systematic Review and Meta-analysis

Background and objective: Enfortumab vedotin (EV) is emerging as a standard of care for advanced urothelial carcinoma (UC), but identification of which patients might benefit the most or least remains an unmet need. Our aim was to identify clinical and molecular parameters associated with EV sensiti...

Descripción completa

Detalles Bibliográficos

Autores principales:	Mohammed Altenni, Péter Fehérvári, Jakub Hoferica, Péter Hegyi, Nándor Ács, Tamás Fazekas, Judit Vargha, Viktor Grünwald, Christopher Darr, Péter Riesz, Péter Nyirády, Tibor Szarvas
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2025-12-01
Colección:	European Urology Open Science
Materias:	Enfortumab vedotin NECTIN4 FGFR Immune checkpoint inhibitor Urothelial carcinoma Meta-analysis
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S2666168325014417
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!